BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BC Extra | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges...
BC Extra | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Week In Review | Nov 9, 2018
Clinical News

Lilly drops BACE inhibitors for Alzheimer’s

Eli Lilly and Co. (NYSE:LLY) discontinued the combination arm evaluating anti-β-amyloid mAb LY3002813 plus BACE inhibitor LY3202626 in the Phase II TRAILBLAZER-ALZ trial to treat Alzheimer's disease. Spokesperson Nicole Herbert told BioCentury that Lilly has...
BC Week In Review | Oct 26, 2018
Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to treat...
BC Extra | Oct 25, 2018
Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 Thursday that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to...
BC Week In Review | Jul 27, 2018
Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) reported data from the Phase II Study 202 for their β-site APP-cleaving enzyme 1 (BACE1) inhibitor elenbecestat (E2609) showing that the therapy reduced amyloid plaques and slowed...
Items per page:
1 - 10 of 138